<DOC>
	<DOCNO>NCT02436772</DOCNO>
	<brief_summary>This study evaluate performance blood test detect biomarkers metastatic breast cancer patient one clinic standard testing .</brief_summary>
	<brief_title>Utilization OncoCEE™ Platform Evaluate Selected Biomarker Alterations CTCs Isolated From Patients With MBC</brief_title>
	<detailed_description>The primary objective pilot study detect expression FGFR1 AR circulate tumor cell ( CTCs ) isolate peripheral blood metastatic breast cancer ( MBC ) patient use OncoCEE™ platform . No procedure associate study , mutation evaluate leftover blood already send standard care ER HER2 use platform . Results test correlated result obtain standard test calculate rate concordance test .</detailed_description>
	<criteria>Current patient participate clinic Metastatic breast cancer diagnosis 18 year age old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>